Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) EPS (Weighted Average and Diluted) (2020 - 2025)

Black Diamond Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.26 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 7.14% year-over-year to -$0.26; the TTM value through Dec 2025 reached $0.38, up 129.92%, while the annual FY2025 figure was $0.39, 130.71% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.26 in Q4 2025 per BDTX's latest filing, down from -$0.15 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.98 in Q1 2025 to a low of -$0.97 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.33, with a median of -$0.28 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 131.71% in 2021, then skyrocketed 380.0% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.97 in 2021, then soared by 71.13% to -$0.28 in 2024, then grew by 7.14% to -$0.26 in 2025.
  • Per Business Quant, the three most recent readings for BDTX's EPS (Weighted Average and Diluted) are -$0.26 (Q4 2025), -$0.15 (Q3 2025), and -$0.19 (Q2 2025).